Lisinopril renal
Searched over 200M research papers for "lisinopril renal"
Summary
10 papers analyzed
These studies suggest that lisinopril slows the progression of renal disease in various patient groups, including those with type II diabetes mellitus, normotensive insulin-dependent diabetes, and non-diabetic chronic renal diseases, while also reducing proteinuria and having specific renoprotective effects.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
The Impact of Lisinopril on Renal Health
Introduction to Lisinopril and Renal Function
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used to manage hypertension and heart failure. Its role in protecting renal function, particularly in patients with diabetes and other chronic kidney conditions, has been extensively studied. This article synthesizes findings from multiple studies to elucidate the effects of lisinopril on renal health.
Lisinopril in Diabetic Nephropathy
Normotensive IDDM Patients
Research has shown that lisinopril can slow the progression of renal disease in normotensive patients with insulin-dependent diabetes mellitus (IDDM). A study involving 530 IDDM patients demonstrated that lisinopril significantly reduced the albumin excretion rate (AER) over two years, particularly in those with microalbuminuria . This suggests that early intervention with lisinopril can be beneficial even before significant albuminuria develops.
Genetic Factors and Renal Disease Progression
The EURODIAB Controlled Trial highlighted the influence of ACE gene polymorphisms on the progression of renal disease in IDDM patients. Patients with the II genotype showed the fastest progression of AER on placebo but responded most favorably to lisinopril, with a 51.3% reduction in AER compared to placebo. This indicates that genetic factors may modulate the effectiveness of lisinopril in preventing renal disease progression.
Lisinopril in Non-Diabetic Nephropathies
Mild Proteinuric Non-Diabetic Nephropathies
In patients with non-diabetic chronic renal diseases and mild proteinuria, lisinopril has been shown to slow the decline in renal function more effectively than other antihypertensive agents. Over a follow-up period of approximately 22.5 months, patients treated with lisinopril experienced a significantly smaller decline in renal function compared to those on alternative therapies. This supports the renoprotective effects of lisinopril beyond its blood pressure-lowering capabilities.
Chronic Allograft Nephropathy
For patients with chronic allograft nephropathy, lisinopril has been found to reduce proteinuria and preserve graft function. A study involving 47 patients showed that lisinopril significantly decreased proteinuria and improved markers of renal tubular function without adversely affecting the rate of graft function decline. This suggests that lisinopril can be safely used to manage proteinuria in renal transplant recipients.
Comparative Studies with Other Antihypertensives
Lisinopril vs. Nifedipine
Comparative studies between lisinopril and nifedipine, a calcium channel blocker, have shown mixed results. In hypertensive renal transplant recipients, nifedipine was found to improve kidney transplant function more than lisinopril over two years. However, both drugs were equally effective in reducing left ventricular mass, an important cardiovascular risk factor. This indicates that while lisinopril is beneficial for renal protection, its effects may vary depending on the specific patient population and condition.
Lisinopril vs. Atenolol
In hypertensive non-insulin-dependent diabetes mellitus (NIDDM) patients with diabetic nephropathy, lisinopril and atenolol were equally effective in reducing the decline in kidney function. However, lisinopril was more effective in reducing urinary albumin excretion, highlighting its superior renoprotective properties in this patient group.
Conclusion
Lisinopril has demonstrated significant benefits in slowing the progression of renal disease across various patient populations, particularly those with diabetes and mild proteinuria. Its effectiveness can be influenced by genetic factors, and while it compares favorably with other antihypertensive agents in many scenarios, the choice of treatment should be tailored to individual patient needs and conditions. Overall, lisinopril remains a valuable tool in the management of renal health.
Sources and full results
Most relevant research papers on this topic
